Bookmark

Add to MyYahoo RSS

Dendreon News

News on Dendreon (Ticker: DNDN) continually updated from thousands of sources around the net.

Wednesday Aug 20 | AmericanBankingNews.com

Recent Investment Analysts' Ratings Updates for Dendreon

Dendreon had its price target lowered by analysts at Jefferies Group from $2.00 to $1.50.

Comment?

Related Topix: Financial Services, Investment Banking, Jefferies Group, Investment Services

Wednesday Aug 20 | AmericanBankingNews.com

Dendreon (DNDN) Releases Quarterly Earnings Results, Hits Estimates

Dendreon released its earnings data on Wednesday. The company reported earnings per share for the quarter, meeting the analysts' consensus estimate of , American Banking and Market News reports.

Comment?

Tue Aug 19, 2014

Business Journal

Regulatory woes: Did a 3-year FDA delay doom Dendreon's prostate cancer drug?

Did delays in winning FDA to approve for the innovative prostate cancer drug Provenge cause Dendreon to borrow so much money that the Seattle company now faces the possibility of defaulting on its debt? Joseph Gulfo , a doctor who has written a new book on the U.S. Food and Drug Administration's approval process, said the FDA did not understand ... (more)

Comment?

Related Topix: Food and Drug Administration

Fri Aug 15, 2014

GuruFocus.com

A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

Biotechnology organization Dendreon is not healthy in 2014. The organization has lost considerable value year-to-date and its first-quarter results didn't inspire any trust either, despite the fact that they were marginally better as compared to last year.

Comment?

Thu Aug 14, 2014

AmericanBankingNews.com

Dendreon's Neutral Rating Reaffirmed at Zacks

's stock had its "neutral" rating reaffirmed by Zacks in a research note issued to investors on Thursday.

Comment?

Wed Aug 13, 2014

Seeking Alpha

Dendreon: Is The End Near?

Dendreon Corporation shareholders got a piece of bad news a few days ago, when the company announced that it was looking at ways to pay off its debt that could include measures that would leave shareholders with little to no holdings in the company.

Comment?

AmericanBankingNews.com

Dendreon Rating Reiterated by Credit Suisse

's stock had its "neutral" rating reaffirmed by research analysts at Credit Suisse in a report released on Wednesday.

Comment?

BioSpace

Struggling Dendreon Corporation Plunges After Warning Investors Of Debt Woes

Dendreon Corp. , the maker of prostate-cancer drug Provenge, plunged after the company said it's considering steps that may leave the shares worthless.

Comment?

Tue Aug 12, 2014

Seeking Alpha

Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

Tumor cells that refuse to die have led researchers to develop immuno-oncology drugs, a brand new class, with Big Pharma participation.

Comment?

Related Topix: Oncology, Medicine, Biotech, Bristol Myers Squibb, Healthcare Industry, Medarex, Merck , Merck & Co.

SchaeffersResearch.com

Analyst Downgrades: Dendreon Corporation, MannKind Corporation, and magicJack VocalTec Ltd

Following this news, Jefferies dropped its price target on Dendreon Corporation to $1.50 from $2 and backed its "underperform" rating, while Cowen and Company reduced its target to $2.33 from $2.55 and reiterated a "market perform" opinion.

Comment?

Related Topix: Financial Markets, Personal Finance, Day Trading

TheStreet.com

Why Dendreon (DNDN) Stock Hit a One-Year Low Today

"Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon," the company said in the filing.

Comment?

Seeking Alpha

Dendreon Provides A Major Warning To Shareholders

I've spent a lot of time detailing the short thesis for biotech name Dendreon . Shares of the company have continued to plunge, and closed at just $2.12 yesterday.

Comment?

Washington Examiner

Dendreon sinks after drugmaker warns of debt woes

Dendreon Corp. shares tumbled Tuesday morning, a day after the drug developer warned shareholders that it has debt worries, and it is considering alternatives that could wipe out their ownership.

Comment?

Related Topix: Medicine, Cancer, Health, Prostate Cancer

Mon Aug 11, 2014

AmericanBankingNews.com

Dendreon (DNDN) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Dendreon posted its quarterly earnings results on Monday. The company reported EPS for the quarter, beating the Thomson Reuters consensus estimate of by $0.15, Analyst Ratings Net reports.

Comment?

Fri Aug 08, 2014

BayStreet.ca

Small companies lead the I-O class of Cancer Therapies

Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades.

Comment?

Related Topix: Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Oncology, Medarex, Merck , Merck & Co.

Wed Aug 06, 2014

Hispanic Business

Dendreon Names W. Thomas Amick President and Chief Executive Officer

Most recently from 2010 to 2012, he served as chairman and chief executive officer of where, as vice president of the Ortho Biotech Oncology Franchise, he launched Procrit and built J&J's oncology franchise into a multi-billion dollar operation, making Procrit the most successful product in J&J history at the time.

Comment?

Related Topix: Oncology, Medicine, Biotech, Science / Technology, Epogen, Procrit, Epoetin Alfa (generic)

Wed Jul 30, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

The company operates over 500 storage facilities in 25 states under the... )--A10 Networks, Inc. , a technology leader in application networking, today announced financial results for its second quarter ended June 30, 2014.

Comment?

Related Topix: World Fuel Services Corporation, Energy, Oil & Gas, Real Estate, Sovran Self Storage

Freshnews

Dendreon Names W. Thomas Amick President and Chief Executive Officer

Dendreon Corporation today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Discovery Laboratories, Healthcare Industry, Johnson & Johnson, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••